Composition

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas

Retrieved on: 
Thursday, December 28, 2023
Annex, Risk, FDA, Brussels Stock Exchange, CDO, Convertible, USD, CSO, Communication, Geographic atrophy, Drug development, CFO, Executive Committee, Bankruptcy, AMD, Disease, Rothschild Bank, Cayman, Debt, EUR, Capital, Therapy, Paratriathlon, Running, Working capital, Person, New Board, Injection, Composition, Composition of matter, Patient, TotalEnergies, Medicine, Partnership, Section 1, Doctor of Philosophy, IVT, Prospectus, LOI, Negotiation, Retina, Security (finance)

Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.

Key Points: 
  • Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.
  • Earlier this year the FDA approved the first medicine for the treatment of GA, SYFOVRE®1 (pegcetacoplan injection) from Apellis.
  • In August of this year, a second product was approved for GA, IZERVAY™2(avacincaptad pegol intravitreal solution) from Iveric Bio, an Astellas company, with a similar profile to SYFOVE.
  • In the event the total Working Capital costs would amount to the total remaining amount under the Atlas funding program, i.e.

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s

Retrieved on: 
Tuesday, December 19, 2023
Research, General Health, Cannabis, Pharmaceutical, Mental Health, Technology, Natural Resources, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Quality of life, Alzheimer's disease, Agitation, Caregiver, Caregiver burden, Composition, Patent, Treating, Public, CNS, Disorder, LMP, CB1, Somatic symptom disorder, Patient, IGC, Central nervous system, Pharmaceutical industry

IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS).

Key Points: 
  • IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS).
  • IGC Pharma has strategically sought patent protection for the IGC-AD1 formulation in many jurisdictions including the U.S., Europe, Canada, and Mexico.
  • Today’s announcement of the issuance of the patent for the drug formulation that targets Central Nervous System (CNS) Disorders marks an important milestone in helping set the stage for potential commercialization.
  • IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer's disease.

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
Monday, November 13, 2023
Agriculture, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Mental Health, Cannabis, Clinical Trials, Composition, Shingles, Fibromyalgia, Cannabinoid, Research, NYSE, Treating, Scleroderma, IND, Epilepsy, Administration, Patient, IGC, Intelligence, Canadian Intellectual Property Office, Agitation, Dementia, LMP, Psoriatic arthritis, Human, Pain, Patent, Pharmaceutical industry, Cryptocurrency

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).
  • Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000.
  • In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year’s six-month period.
  • The Company continues to drive progress with ten sites in the United States and Canada, currently conducting the trial.

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

Retrieved on: 
Monday, December 18, 2023
CNS, World Health Organization, Composition, Urinary tract infection, Dark Enlightenment, Urine, QIDP, IND, GWU, Baylor University, DCS, Nick Cuti, Learning, Hope, NMDA, Sepsis, Patient, FDA, UTI, Friends, George Washington University, Tropical medicine, Bacteria, University, Composition of matter, MD, Accenture, Engineering, Death, Failure, Microbiology, Hospital, GSK plc, Pharmaceutical industry, Urology, Immunology

"Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.

Key Points: 
  • "Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.
  • New treatment options are urgently needed" stated Jonathan Javitt, MD MPH, Founder and Chief Scientist of NRx Pharmaceuticals.
  • "The D-cycloserine (DCS) component of NRX-101 is well known as an antibiotic and is excreted unmetabolized in the urine.
  • The company awaits the FDA's response to its request for Qualified Infectious Disease Product (QIDP) designation, expected next month.

Shredder Blades Market worth $557 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, December 15, 2023
Carbon, ASR, Plastic, Composition, Glass, Waste management, Research, Biomass, Recycling, Urbanization, Atmosphere of Earth, Wood, Health, Table tennis rubber, Food industry, Glass fiber, Carbon-fiber-reinforced polymers, Growth, Pulp, Geography, Power, Environment, Magnetism, Region

Based on application, the Shredder Blades Market has been split into into plastic, rubber, metal, wood, e-waste, paper & cardboard, others (fabric, biomass, glass, food processing, food waste).

Key Points: 
  • Based on application, the Shredder Blades Market has been split into into plastic, rubber, metal, wood, e-waste, paper & cardboard, others (fabric, biomass, glass, food processing, food waste).
  • Shredder blades are versatile tools with a wide range of applications across various industries.
  • Type of shredder blades needed to be used for particular application depends on material needed to be shredded.
  • Based on End user industry, Shredder Blades Market is divided into Waste management & recycling, food industry, pharmaceutical & others (Power generation and Pulp& Paper).

Shredder Blades Market worth $557 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, December 15, 2023
Carbon, ASR, Plastic, Composition, Glass, Waste management, Research, Biomass, Recycling, Urbanization, Atmosphere of Earth, Wood, Health, Table tennis rubber, Food industry, Glass fiber, Carbon-fiber-reinforced polymers, Growth, Pulp, Geography, Power, Environment, Magnetism, Region

Based on application, the Shredder Blades Market has been split into into plastic, rubber, metal, wood, e-waste, paper & cardboard, others (fabric, biomass, glass, food processing, food waste).

Key Points: 
  • Based on application, the Shredder Blades Market has been split into into plastic, rubber, metal, wood, e-waste, paper & cardboard, others (fabric, biomass, glass, food processing, food waste).
  • Shredder blades are versatile tools with a wide range of applications across various industries.
  • Type of shredder blades needed to be used for particular application depends on material needed to be shredded.
  • Based on End user industry, Shredder Blades Market is divided into Waste management & recycling, food industry, pharmaceutical & others (Power generation and Pulp& Paper).

New Book Provides Comprehensive Guide to Using AI in the Music Industry

Retrieved on: 
Tuesday, November 28, 2023
Intelligence, Composition, Fear, Synovial joint, AI, Learning curve, Creativity, Handbook, Algorithm, Interview, Video, Music, Customer service, Medical device

LOS ANGELES, Nov. 28, 2023 /PRNewswire/ -- Today, renowned author, teacher, producer, and engineer Bobby Owsinski announced the release of his new book, The Musician's AI Handbook.

Key Points: 
  • LOS ANGELES, Nov. 28, 2023 /PRNewswire/ -- Today, renowned author, teacher, producer, and engineer Bobby Owsinski announced the release of his new book, The Musician's AI Handbook.
  • The book is packed with useful information and how-to's, covering everything from the basics of AI to the latest advances in AI-powered music generation, production, mixing, mastering, graphics, video, and chatbots.
  • It also explores the legal and ethical considerations of using AI in music, as well as the benefits and limitations of the various AI platforms.
  • The Musician's AI Handbook is more than just a manual; it's a reassurance for those who fear AI might stifle their creativity or outpace their learning curve.

Ecological Huaiyin with Enchanting Colors

Retrieved on: 
Thursday, November 16, 2023
Composition, Eye, Civilization, Nature, Heart, Yellow, Blue, News, Atmosphere, Water, Freedom, Huaiyin, Walking, Life, Frolic

In this city, where beautiful and vibrant colors can be found throughout the year, one can witness ecological harmony and charm everywhere.

Key Points: 
  • In this city, where beautiful and vibrant colors can be found throughout the year, one can witness ecological harmony and charm everywhere.
  • As autumn arrives each year, the rice fields along the banks of the Yellow River officially enter the harvest season.
  • If people are looking to escape the bustle of the city for a while, consider taking a walk westward from Huaiyin along the Yellow River.
  • In the surrounding forest, squirrels frolic, contributing to the sense of freedom within this harmonious coexistence with nature.

Macmillan Learning Introduces Bedford Bookshelf for American History and for English Composition

Retrieved on: 
Thursday, November 9, 2023
Technology, Publishing, Entertainment, Communications, Books, Internet, Continuing, University, Education, Composition, Achievement Test in English Composition, Catalog, History of the United States, Associate, History, Belmont University, Reading, Bedford/St. Martin's, Humanities, Student, Bookcase, Collection, Languages of Ethiopia, Louisiana State University, Book, English

“The Bedford Bookshelf offers instructors an unmatched level of flexibility in their courses, while at the same time providing students with multiple lenses to view American history and Composition,” said Leasa Burton, VP of Humanities at Macmillan Learning. “Exploring many perspectives in history and writing is like adjusting a kaleidoscope -- with each turn, students can see a different pattern, gain a deeper understanding, and appreciate the complexity of important topics and concepts."

Key Points: 
  • The Bedford Bookshelf from the Bedford / St. Martin's imprint will be available Spring 2024 for two disciplines: American History and English Composition.
  • “The Bedford Bookshelf offers instructors an unmatched level of flexibility in their courses, while at the same time providing students with multiple lenses to view American history and Composition,” said Leasa Burton, VP of Humanities at Macmillan Learning.
  • The Bedford Bookshelf for American History was crafted with flexibility in mind to help educators weave a multi-faceted narrative of America's past.
  • “The Bedford Bookshelf for American History was a huge success in my Southern History class.

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Technology, Infectious Diseases, Health, Artificial Intelligence, WHO, Bioinformatics, LG Chem, Drug design, Intelligence, Composition, Incidence, Pregnancy, Vaccine, Government, ROW, Prevalence, Indian Immunologicals Limited, GSK plc, Merck, Data science, Mother, Vaccination, Liver cancer, Genomics, Transport, COVAX, COVID-19, Antibody, KM, Microbiology, Machine learning, Biochemistry, Blood, Hepatitis A and B vaccine, Serum, Hepatitis B virus, Public, Sanofi, Hepatitis, Hepatitis B, Immunization, Pediatrics, World Health Organization's response to the COVID-19 pandemic, Compound annual growth rate, HBV, Parent, Cirrhosis, Merck & Co.

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.